Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.

Unger WW, Pearson T, Abreu JR, Laban S, van der Slik AR, der Kracht SM, Kester MG, Serreze DV, Shultz LD, Griffioen M, Drijfhout JW, Greiner DL, Roep BO.

PLoS One. 2012;7(11):e49213. doi: 10.1371/journal.pone.0049213. Epub 2012 Nov 14.

2.

Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach.

Niens M, Grier AE, Marron M, Kay TW, Greiner DL, Serreze DV.

Diabetes. 2011 Apr;60(4):1229-36. doi: 10.2337/db10-1523. Epub 2011 Feb 23.

3.

Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice.

Enée E, Martinuzzi E, Blancou P, Bach JM, Mallone R, van Endert P.

J Immunol. 2008 Apr 15;180(8):5430-8.

4.

Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.

Babad J, Mukherjee G, Follenzi A, Ali R, Roep BO, Shultz LD, Santamaria P, Yang OO, Goldstein H, Greiner DL, DiLorenzo TP.

Clin Exp Immunol. 2015 Mar;179(3):398-413. doi: 10.1111/cei.12465.

5.

HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, but not nondiabetic donors, transfer insulitis to NOD-scid/γc(null)/HLA-A2 transgenic mice concurrent with the expansion of islet-specific CD8+ T cells.

Whitfield-Larry F, Young EF, Talmage G, Fudge E, Azam A, Patel S, Largay J, Byrd W, Buse J, Calikoglu AS, Shultz LD, Frelinger JA.

Diabetes. 2011 Jun;60(6):1726-33. doi: 10.2337/db10-1287. Epub 2011 Apr 26.

6.

"Humanized" HLA transgenic NOD mice to identify pancreatic beta cell autoantigens of potential clinical relevance to type 1 diabetes.

Serreze DV, Marron MP, Dilorenzo TP.

Ann N Y Acad Sci. 2007 Apr;1103:103-11. Epub 2007 Mar 21.

PMID:
17376821
7.

HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes.

Takaki T, Marron MP, Mathews CE, Guttmann ST, Bottino R, Trucco M, DiLorenzo TP, Serreze DV.

J Immunol. 2006 Mar 1;176(5):3257-65.

8.

Identification of novel IGRP epitopes targeted in type 1 diabetes patients.

Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP.

Clin Immunol. 2008 Jun;127(3):359-65. doi: 10.1016/j.clim.2008.01.015. Epub 2008 Mar 20.

9.

The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment.

Martinuzzi E, Novelli G, Scotto M, Blancou P, Bach JM, Chaillous L, Bruno G, Chatenoud L, van Endert P, Mallone R.

Diabetes. 2008 May;57(5):1312-20. doi: 10.2337/db07-1594. Epub 2008 Feb 27.

10.

Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.

Antal Z, Baker JC, Smith C, Jarchum I, Babad J, Mukherjee G, Yang Y, Sidney J, Sette A, Santamaria P, DiLorenzo TP.

J Immunol. 2012 Jun 1;188(11):5766-75. doi: 10.4049/jimmunol.1102930. Epub 2012 Apr 25.

11.

Genetic and therapeutic control of diabetogenic CD8+ T cells.

Santamaria P.

Novartis Found Symp. 2008;292:130-6; discussion 136-45, 202-3.

PMID:
19209463
12.

HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes.

Scotto M, Afonso G, Østerbye T, Larger E, Luce S, Raverdy C, Novelli G, Bruno G, Gonfroy-Leymarie C, Launay O, Lemonnier FA, Buus S, Carel JC, Boitard C, Mallone R.

Diabetes. 2012 Oct;61(10):2546-55.

13.

Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice.

Marron MP, Graser RT, Chapman HD, Serreze DV.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13753-8. Epub 2002 Oct 2.

14.

Identification of autoreactive CD8+ T cell responses targeting chromogranin A in humanized NOD mice and type 1 diabetes patients.

Li Y, Zhou L, Li Y, Zhang J, Guo B, Meng G, Chen X, Zheng Q, Zhang L, Zhang M, Wang L.

Clin Immunol. 2015 Jul;159(1):63-71. doi: 10.1016/j.clim.2015.04.017. Epub 2015 May 6.

15.

CD8 and cytotoxic T cells in type 1 diabetes.

Peakman M.

Novartis Found Symp. 2008;292:113-9; discussion 119-29, 202-3.

PMID:
19203096
16.

Characterization of immune response to novel HLA-A2-restricted epitopes from zinc transporter 8 in type 1 diabetes.

Xu X, Gu Y, Bian L, Shi Y, Cai Y, Chen Y, Chen H, Qian L, Wu X, Xu K, Mallone R, Davidson HW, Yu L, She J, Zhang M, Yang T.

Vaccine. 2016 Feb 3;34(6):854-62. doi: 10.1016/j.vaccine.2015.10.108. Epub 2015 Nov 3.

PMID:
26541133
17.

Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.

Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Xiang J.

Vaccine. 2012 May 21;30(24):3519-25. doi: 10.1016/j.vaccine.2012.03.075. Epub 2012 Apr 6.

PMID:
22484292
18.
19.

HLA class I epitope discovery in type 1 diabetes.

van Endert P, Hassainya Y, Lindo V, Bach JM, Blancou P, Lemonnier F, Mallone R.

Ann N Y Acad Sci. 2006 Oct;1079:190-7.

PMID:
17130554
20.

Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.

Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW.

J Clin Invest. 2006 Dec;116(12):3258-65.

Supplemental Content

Support Center